Merck recognized for digital workplace platform

MerckThe new EVA digital workplace at Merck, a leading science and technology company, was recently recognized with multiple Ragan Intranet Awards, an internationally renowned competition. The platform received prizes in the "Best Internal Social Networking" and "Best Design" categories. It also garnered an honorable mention in the "Grand Prize: Best Overall Intranet" category.

EVA, a digital workplace for internal collaboration and knowledge sharing, has been available to all Merck employees Group-wide since September 2015, when it replaced the existing intranet. EVA stands for "Expertise everywhere, Virtual teams, Access to information" and represents an important step towards digitizing communication and collaboration. "Our value proposition as an employer is defined by more than competitive salaries and benefits," says Kai Beckmann, Merck Executive Board Member responsible for Human Resources and IT, among other areas. "Digital workplaces in innovation-driven growth businesses make Merck an attractive employer for the talent we need."

EVA brings Merck employees together from across the globe, uniting them in one large community. The system is broken down into different rooms that represent organizations, projects, topics, processes, or sites; these in turn likewise function as platforms for sharing ideas and communicating. Using EVA, virtual teams can be formed across departmental boundaries and national borders, exchanging knowledge and best practices. A total of around 40,000 users have access to the system.

"EVA is already seeing heavy use. In response to Merck's rebranding alone, employees posted hundreds of comments and thousands of likes within a very short period of time," notes Frank Sielaff, Head of Digital Media Merck Communications and project leader for EVA. "EVA was developed and launched in close collaboration with Group Communications and Merck IT."

EVA’s launch is yet another step toward creating a modern, future-oriented work environment, which also includes flexible working hour models such as MyWork@Merck. This initiative enables many employees to freely choose when and where they work. The new Innovation Center in Darmstadt also offers an inspiring, motivating environment. Here, employees can collaborate in an open atmosphere to find creative solutions as well as try out new approaches to project work.

According to Ragan’s website, its award competitions are the most prestigious in the PR and corporate communications industry. With nearly 800,000 users per month, the platform serves as a source of information for communications professionals around the world.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...